Table 3.

Cox model results for time to prostate cancer diagnosis by miRNA binding region variants among PRAP Participants with ≥ 1 Follow-Up Visit

		African American participants					Caucasian participants
miRNA Binding site variants	Genotype comparisons	Sample Size*	HR**	95% CI	Unadjusted p-value	FDR corrected p-value***	Sample Size*	HR**	95% CI	Unadjusted p-value	FDR corrected p-value***
IL-16 (rs1131445)	TT vs CC/CT	256	3.00	1.26-7.12	0.013	0.065	207	0.74	0.31-1.78	0.503	0.838
	CC vs TT/CT	256	0.0+	--	0.988	0.988	207	0.0+	--	0.992	0.992
ALOX15 (rs916055)	AA vs GG/AG	255	1.29	0.55-3.05	0.559	0.932	204	0.54	0.19-1.49	0.233	0.583
	GG vs AA/AG			MNR#			204	1.25	0.40-3.90	0.695	0.869
RAF1 (rs1051208)	AA vs GG/AG	257	0.97	0.22-4.34	0.970	0.988			MNR#
	GG vs AA/AG	257	0.75	0.33-1.68	0.478	0.932	207	2.86	0.82-10.03	0.100	0.500

^*Sample sizes vary by number with complete genotype and PSA data available.

^**HR = Hazard ratio after controlling for age, PSA, BMI, and smoking.

^***False Discovery Rated p-value, adjusted for multiple comparisons within race group using Benjamini-Hochberg method.

⁺No prostate cancers with CC genotype

^#MNR = model not run, subgroup < 10 patients